Godavari Drugs Q4 FY26: Profit up 45%, sales 30%

Key takeaway from the March 2026 quarter

Godavari Drugs reported a stronger March 2026 quarter on the back of higher sales, with profit rising faster than revenue on a year-on-year basis. Standalone net profit for the quarter ended March 2026 increased to Rs 1.29 crore from Rs 0.89 crore in the quarter ended March 2025. Net sales for the same period rose to Rs 33.16 crore from Rs 25.50 crore. The company also disclosed that revenue from operations for the quarter was Rs 33.16 crore, while total revenue stood slightly higher at Rs 33.30 crore.

At the same time, operating profitability in the quarter was softer on one key measure. EBITDA for the March 2026 quarter was reported at Rs 3.08 crore, compared with Rs 3.22 crore a year earlier, indicating a decline in operating earnings even as sales improved. The mix of a higher net profit with a lower EBITDA highlights that investors may need to track below-EBITDA items and cost lines across the income statement for a fuller picture.

Quarterly performance: sales growth and profit expansion

For the quarter ended March 2026, Godavari Drugs posted net sales of Rs 33.16 crore, up 30.04% from Rs 25.50 crore in the March 2025 quarter. Net profit for the quarter rose 44.94% to Rs 1.29 crore from Rs 0.89 crore. The reported standalone numbers also describe the quarterly net profit increase as 44.53%, based on the same profit values, pointing to a broadly similar year-on-year profit jump of about 45%.

The company’s revenue from operations for the quarter was reported at Rs 33.16 crore. It also disclosed total revenue of Rs 33.30 crore for the quarter ended March 31, 2026, which is marginally higher than revenue from operations. These figures indicate the presence of a small component of other income or non-operating revenue lines within total revenue for the quarter.

EBITDA: operating profit declined despite higher revenue

Godavari Drugs’ EBITDA stood at Rs 3.08 crore in the March 2026 quarter, down 4.35% from Rs 3.22 crore in the March 2025 quarter. This divergence between sales growth and EBITDA decline suggests operating costs moved up or margins tightened during the period.

While the article data does not provide detailed expense break-ups, the EBITDA movement is a key datapoint because it reflects core operating profitability before interest, tax, depreciation and amortisation. With net profit rising sharply year-on-year in the same quarter, the financial outcome may also have been influenced by factors outside EBITDA, such as depreciation, finance costs, taxes, or other income.

Full-year FY26: profit and revenue fell versus FY25

For the full year ended March 2026, Godavari Drugs reported net profit of Rs 4.09 crore, compared with Rs 4.38 crore in the previous year ended March 2025. This represents a decline of 6.62% year-on-year. Full-year sales for FY26 were Rs 105.81 crore, down 6.65% from Rs 113.35 crore in FY25.

The company also reported its annual numbers in lakh, which align with the crore figures above. For FY26, net profit was stated as Rs 4.09 crore (Rs 408.91 lakh) on revenue from operations of Rs 105.81 crore (Rs 10,580.81 lakh). For FY25, net profit was Rs 4.38 crore (Rs 438.00 lakh), with revenue from operations of Rs 113.35 crore (Rs 11,335.01 lakh).

How Q4 strength fits into the FY26 trend

The March quarter performance shows a rebound versus the March 2025 quarter, but the full-year picture indicates that FY26 ended with lower profit and revenue than FY25. This combination, stronger Q4 but weaker full year, often points to volatility across quarters or a softer performance earlier in the year that was not fully offset by the final quarter’s growth.

The article data also references another recent quarter: net profit declined 1.30% to Rs 0.76 crore in the quarter ended December 2025, compared with Rs 0.77 crore in the quarter ended December 2024. This provides additional context that performance across FY26 may have been uneven across quarters.

Key financial snapshot

Longer-term profitability context mentioned in the data

Beyond the latest quarterly and annual results, the dataset notes a longer trend: over the last five years, net income has grown at a yearly rate of 16.86%, compared with an industry average of 19.69%. This comparison provides a broader benchmark, indicating that the company’s historical net income growth, as stated, trails the cited industry average.

The same dataset includes a “Last Earnings Date” reference and some fields such as revenue and net profit values for “Q0 FY25-26”, but the units and the meaning of those fields are not clearly specified alongside the numbers. As a result, the most directly comparable and clearly defined performance indicators remain the March 2026 quarter and FY26 figures provided in the standalone results.

Market impact: what investors typically track from these numbers

The March 2026 quarter highlights strong year-on-year growth in net sales and net profit, which typically draws attention to the company’s near-term momentum. However, the EBITDA decline in the same quarter and the year-on-year decline in full-year FY26 sales and profit can lead investors to focus on operating margins, cost trends, and the sustainability of the Q4 improvement.

No stock price movement, guidance, or management commentary is included in the provided data. In the absence of those details, the key market-relevant signals from this update are the contrast between Q4 acceleration and FY26 contraction, plus the reported decline in EBITDA in the March 2026 quarter.

Conclusion

Godavari Drugs closed the March 2026 quarter with net profit of Rs 1.29 crore on net sales of Rs 33.16 crore, alongside EBITDA of Rs 3.08 crore. For FY26, net profit fell to Rs 4.09 crore and sales declined to Rs 105.81 crore versus FY25. The next set of quarterly disclosures will be important to confirm whether the March quarter sales growth is sustained and whether operating profitability, as reflected in EBITDA, improves from the March 2026 level.